SCARNA21B

Across TCGA pan-cancer cohorts, SCARNA21B RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated SCARNA21B data layer.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SCARNA21B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCARNA21B expression acts as an unfavorable survival marker, although some lineages such as BRCA and CESC show a favorable association.

DLBC, MESO, and SKCM are the cancer types where SCARNA21B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Tertile	II,III,IV	0.065	0.829	<.001	72	view →
MESO	DFS	Tertile	All	0.092	0.380	<.001	72	view →
SKCM	DFS	Tertile	III,IV	0.043	0.597	<.001	54	view →
PCPG	OS	Tertile	All	0.010	0.946	<.001	27	view →
LIHC	DFS	Tertile	All	0.144	0.309	.015	24	view →
BRCA	OS	Tertile	III,IV	1.000	0.892	.032	12	view →
CESC	OS	Tertile	All	1.000	0.783	.031	12	view →
STAD	OS	Tertile	IV	0.857	0.404	.019	12	view →
LGG	DFS	Tertile	All	0.265	0.415	.030	6	view →
GBM	DFS	Tertile	All	0.481	0.218	.039	3	view →
KIRP	OS	Tertile	All	0.835	0.939	.018	3	view →
ESCA	DFS	Quartile	III,IV	0.483	0.242	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

SCARNA21B–DLBC (DFS)

Open the DLBC breakdown →